SCIG Hizentra denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for scig hizentra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Quantity Limits to Hizentra

Aetna imposes quantity limits on Hizentra as a cost and utilization management measure. The default authorized quantity is tied to a weight-based or standardized dosing assumption in Aetna's policy. A quantity-limit denial occurs when the requested amount exceeds that default — typically because the patient's clinical needs, body weight, or prescriber-determined dosing regimen requires a quantity above what Aetna's policy automatically approves. This is a denial of the specific amount requested, not of the drug itself.

## Why This Denial Is Appealable

Hizentra dosing is individualized. The FDA-approved prescribing information specifies that dosing is determined by the patient's clinical response, body weight, and prior IgG levels — not by a plan-defined default quantity. When the prescribed quantity is clinically justified and consistent with the label, Aetna's quantity limit is challengeable. The prescriber's clinical judgment takes precedence when properly documented.

## Federal Appeal Framework

• Internal appeal: File within the plan deadline. This type of appeal is often resolved quickly when weight-based or clinical dosing rationale is submitted.
• Expedited review: If the patient is currently without adequate treatment or faces clinical risk from the quantity restriction, request expedited internal review (72-hour turnaround).
• External review (ACA §2719 / ERISA §503): If internal appeal fails, request IRO review within 4 months. The IRO will evaluate whether the quantity limit is consistent with the FDA label and accepted clinical practice.

## Documentation to Gather

1. Current body weight and clinical parameters — the chart entry showing the weight or lab value used to calculate the prescribed quantity, with the calculation explained. 2. Prescribing label reference — the relevant section of the FDA-approved Hizentra prescribing information describing individualized dosing methodology. 3. Dosing rationale letter — a prescriber letter explaining how the requested quantity was calculated, why it is the minimum clinically appropriate amount, and what clinical risk would result from a reduced quantity. 4. IgG trough levels — if available, include laboratory documentation of IgG levels that support the prescribed dose and frequency. 5. Infusion logs — if the patient has been on Hizentra previously, records of administered quantities and clinical response.

## Criteria-Mapping Strategy

Obtain Aetna's published quantity-limit criteria for immunoglobulin products. Compare the stated default quantity assumptions against the FDA label's dosing guidance and the patient's actual clinical parameters. Document the gap explicitly: state the approved quantity, the requested quantity, and the clinical reason for the difference. This arithmetic transparency is highly persuasive to both internal reviewers and an IRO.